|
[1]
|
Ljunggren, H.G., Jonsson, R. and Höglund, P. (2018) Seminal Immunologic Discoveries with Direct Clinical Implica-tions: The 2018 Nobel Prize in Physiology or Medicine Honours Discoveries in Cancer Immunotherapy. Scandinavian Journal of Immunology, 88, e12731. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Francisco, L.M., Sage, P.T. and Sharpe, A.H. (2010) The PD-1 Pathway in Tolerance and Autoimmunity. Immunological Reviews, 236, 219-242. [Google Scholar] [CrossRef]
|
|
[3]
|
Fife, B.T. and Pauken, K.E. (2011) The Role of the PD-1 Pathway in Autoimmunity and Peripheral Tolerance. Annals of the New York Academy of Sciences, 1217, 45-59. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Sharma, P. and Allison, J.P. (2015) The Future of Immune Checkpoint Therapy. Science, 348, 56-61. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
严时佳, 孙蕾, 万国辉. PD-1/PD-L1免疫治疗在肿瘤中的耐药机制和研究进展[J]. 药学学报, 2019, 54(10): 1728-1734.
|
|
[6]
|
谢同济, 王守正, 邢镨元. 解析PD-1/PD-L1抑制剂分子结构差异与不良反应的相关性[J]. 中国肺癌杂志, 2020, 23(7): 603.
|
|
[7]
|
Wartewig, T., Kurgyis, Z., Keppler, S., et al. (2017) PD-1 Is a Haploinsufficient Suppressor of T Cell Lymphomagenesis. Nature, 552, 121-125. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Blass, E. and Ott, P.A. (2021) Advances in the Development of Person-alized Neoantigen-Based Therapeutic Cancer Vaccines. Nature Reviews Clinical Oncology, 18, 215-229.
|
|
[9]
|
Carreno, B.M., Magrini, V., Becker-Hapak, M., et al. (2015) A Dendritic Cell Vaccine Increases the Breadth and Diversity of Melanoma Neoantigen-Specific T Cells. Science, 348, 803-808. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Rahman, M.M. and McFadden, G. (2020) Oncolytic Virotherapy with Myxoma Virus. Journal of Clinical Medicine, 9, 171. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Joyce, P., Young, L., Quibell, M., et al. (2020) 446 Immunopeptidome Changes Mediated by a Novel ERAP1 Inhibitor Leads to Tumor Growth Inhibition. Journal for ImmunoTherapy of Cancer, 8, A472. [Google Scholar] [CrossRef]
|
|
[12]
|
Liu, X., Bao, X., Hu, M., et al. (2020) Inhibition of PCSK9 Potentiates Immune Checkpoint Therapy for Cancer. Nature, 588, 693-698. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Zhang, J., Endres, S. and Kobold, S. (2019) Enhancing Tumor T Cell Infiltration to Enable Cancer Immunotherapy. Immunotherapy, 11, 201-213. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Peng, D., Kryczek, I., Nagarsheth, N., et al. (2015) Epigenetic Silenc-ing of TH 1-Type Chemokines Shapes Tumour Immunity and Immunotherapy. Nature, 527, 249-253. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Nagarsheth, N., Peng, D., Kryczek, I., et al. (2016) PRC2 Epigenetically Silences Th1-Type Chemokines to Suppress Effector T-Cell Trafficking in Colon Cancer. Cancer Research, 76, 275-282. [Google Scholar] [CrossRef]
|
|
[16]
|
Topper, M.J., Vaz, M., Chiappinelli, K.B., et al. (2017) Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer. Cell, 171, 1284-1300.e21. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Mortezaee, K. (2020) CXCL12/CXCR4 Axis in the Microenvironment of Solid Tumors: A Critical Mediator of Metastasis. Life Sciences, 249, Article ID: 117534. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Tauriello, D.V.F., Palomo-Ponce, S., Stork, D., et al. (2018) TGFβ Drives Immune Evasion in Genetically Reconstituted Colon Cancer Metastasis. Nature, 554, 538-543. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Mariathasan, S., Turley, S.J., Nickles, D., et al. (2018) TGFβ Attenuates Tumour Response to PD-L1 Blockade by Contributing to Exclusion of T Cells. Nature, 554, 544-548. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Kim, H.S., Ahn, J.H., Kim, J.E., et al. (2020) A Phase I Study of TGF-β Inhibitor, Vactosertib in Combination with Imatinib in Patients with Advanced Desmoid Tumor (Aggressive Fibromato-sis). Journal of Clinical Oncology, 38, 11557. [Google Scholar] [CrossRef]
|
|
[21]
|
Huang, Y., Goel, S., Duda, D.G., et al. (2013) Vascular Normalization as an Emerging Strategy to Enhance Cancer Immuno-therapy. Cancer Research, 73, 2943-2948. [Google Scholar] [CrossRef]
|
|
[22]
|
Finn, R.S., Qin, S., Ikeda, M., et al. (2020) Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. New England Journal of Medicine, 382, 1894-1905. [Google Scholar] [CrossRef]
|
|
[23]
|
万萍, 陈昊, 白爱平. 腺苷的免疫调节功能[J]. 世界华人消化杂志, 2014, 22(17): 2379-2384.
|
|
[24]
|
Allard, B., Pommey, S., Smyth, M.J., et al. (2013) Targeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 mAbs. Clinical Cancer Re-search, 19, 5626-5635. [Google Scholar] [CrossRef]
|
|
[25]
|
Koyas, A., Tucer, S., Kayhan, M., et al. (2021) Interleukin-7 Protects CD8+ T Cells from Adenosine-Mediated Immunosuppression. Science Signaling, 14, eabb1269. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Morello, A., Durand, J., Thepenier, V., et al. (2020) Ab-stract 910: A Novel Bifunctional anti-PD-1 IL-7 Fusion Protein to Reinvigorate Exhausted T Cell and Disarms Treg Suppressive Activity. Proceedings: AACR Annual Meeting 2020, Philadelphia, 27-28 April 2020 and 22-24 June 2020.
|
|
[27]
|
Webb, M.W., Sun, J., Sheard, M.A., et al. (2018) Colony Stimulating Factor 1 Receptor Blockade Improves the Efficacy of Chemotherapy against Human Neuroblastoma in the Absence of T Lymphocytes. International Journal of Cancer, 143, 1483-1493. [Google Scholar] [CrossRef] [PubMed]
|
|
[28]
|
Wei, Z., Zhang, X., Yong, T., et al. (2021) Boost-ing Anti-PD-1 Therapy with Metformin-Loaded Macrophage-Derived Microparticles. Nature Communications, 12, 1-20. [Google Scholar] [CrossRef] [PubMed]
|
|
[29]
|
Cai, J., Wang, D., Zhang, G., et al. (2019) The Role of PD-1/PD-L1 Axis in Treg Development and Function: Implications for Cancer Immunotherapy. OncoTargets and Therapy, 12, 8437. [Google Scholar] [CrossRef]
|
|
[30]
|
Sakaguchi, S., Miyara, M., Costantino, C.M., et al. (2010) FOXP3+ Regulatory T Cells in the Human Immune System. Nature Reviews Immunology, 10, 490-500. [Google Scholar] [CrossRef] [PubMed]
|
|
[31]
|
Aksoylar, H.I. and Boussiotis, V.A. (2020) PD-1+ Treg Cells: A Foe in Can-cer Immunotherapy? Nature Immunology, 21, 1311-1312. [Google Scholar] [CrossRef] [PubMed]
|
|
[32]
|
Solomon, I., Amann, M., Goubier, A., et al. (2020) CD25-Treg-Depleting Antibodies Preserving IL-2 Signaling on Effector T Cells Enhance Effector Activation and Anti-tumor Immunity. Nature Cancer, 1, 1153-1166. [Google Scholar] [CrossRef] [PubMed]
|
|
[33]
|
Wang, H., Franco, F. and Ho, P.C. (2017) Metabolic Regulation of Tregs in Cancer: Opportunities for Immunotherapy. Trends in Cancer, 3, 583-592. [Google Scholar] [CrossRef] [PubMed]
|
|
[34]
|
Watson, M.L.J., Vignali, P.D.A., Mullett, S.J., et al. (2021) Metabolic Support of Tumour-Infiltrating Regulatory T Cells by Lactic Acid. Nature, 591, 645-651.
|
|
[35]
|
Wang, H., Franco, F., Tsui, Y.C., et al. (2020) CD36-Mediated Metabolic Adaptation Supports Regulatory T Cell Survival and Function in Tumors. Nature Immunology, 21, 298-308. [Google Scholar] [CrossRef] [PubMed]
|
|
[36]
|
Du, X., Tang, F., Liu, M., et al. (2018) A Reappraisal of CTLA-4 Checkpoint Blockade in Cancer Immunotherapy. Cell Research, 28, 416-432. [Google Scholar] [CrossRef] [PubMed]
|
|
[37]
|
Rotte, A. (2019) Combination of CTLA-4 and PD-1 Blockers for Treatment of Cancer. Journal of Experimental & Clinical Cancer Research, 38, 255. [Google Scholar] [CrossRef] [PubMed]
|
|
[38]
|
Long, L., Zhang, X., Chen, F., et al. (2018) The Promising Im-mune Checkpoint LAG-3: From Tumor Microenvironment to Cancer Immunotherapy. Genes & Cancer, 9, 176. [Google Scholar] [CrossRef] [PubMed]
|
|
[39]
|
Das, M., Zhu, C. and Kuchroo, V.K. (2017) Tim-3 and Its Role in Regulating Anti-Tumor Immunity. Immunological Reviews, 276, 97-111. [Google Scholar] [CrossRef] [PubMed]
|
|
[40]
|
Kuang, Z., Li, L., Zhang, P., et al. (2020) A Novel Antibody Targeting TIM-3 Resulting in Receptor Internalization for Cancer Immunotherapy. Antibody Therapeutics, 3, 227-236. [Google Scholar] [CrossRef] [PubMed]
|
|
[41]
|
Manieri, N.A., Chiang, E.Y. and Grogan, J.L. (2017) TIGIT: A Key In-hibitor of the Cancer Immunity Cycle. Trends in Immunology, 38, 20-28. [Google Scholar] [CrossRef] [PubMed]
|
|
[42]
|
Hung, A.L., Maxwell, R., Theodros, D., et al. (2018) TIGIT and PD-1 Dual Checkpoint Blockade Enhances Antitumor Immunity and Survival in GBM. Oncoimmunology, 7, e1466769. [Google Scholar] [CrossRef]
|
|
[43]
|
Garber, K. (2020) Immune Agonist Antibodies Face Critical Test. Nature Reviews Drug Discovery, 19, 3-5. [Google Scholar] [CrossRef] [PubMed]
|
|
[44]
|
Zheng, L., Judkins, C., Hoare, J., et al. (2020) 812 Urelumab (Anti-CD137 Agonist) in Combination with Vaccine and Nivolumab Treatments Is Safe and Associated with Pathologic Response as Neoadjuvant and Adjuvant Therapy for Resectable Pancreatic Cancer. Journal for ImmunoTherapy of Can-cer, 8, A486-A487. [Google Scholar] [CrossRef]
|
|
[45]
|
Woroniecka, K.I., Rhodin, K.E., Dechant, C., et al. (2020) 4-1BB Agonism Averts TIL Exhaustion and Licenses PD-1 Blockade in Glioblastoma and Other Intracranial Cancers. Clinical Cancer Research, 26, 1349-1358. [Google Scholar] [CrossRef]
|
|
[46]
|
Messenheimer, D.J., et al. (2017) Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40. Clinical Cancer Research, 23, 6165-6177.
|
|
[47]
|
Rahimi Kalateh Shah Mohammad, G., Ghahremanloo, A., Soltani, A., et al. (2020) Cytokines as Po-tential Combination Agents with PD-1/PD-L1 Blockade for Cancer Treatment. Journal of Cellular Physiology, 235, 5449-5460. [Google Scholar] [CrossRef] [PubMed]
|
|
[48]
|
Mullard, A. (2021) Restoring IL-2 to Its Cancer Immunotherapy Glory. Nature Reviews Drug Discovery, 20, 163-165. [Google Scholar] [CrossRef] [PubMed]
|
|
[49]
|
郭寒菲, 白日兰, 崔久嵬. 肺癌免疫检查点抑制剂的联合治疗研究进展[J]. 中国肺癌杂志, 2020, 23(2): 101.
|
|
[50]
|
Knudson, K.M., Hicks, K.C., Alter, S., et al. (2019) Mecha-nisms Involved in IL-15 Superagonist Enhancement of Anti-PD-L1 Therapy. Journal for Immunotherapy of Cancer, 7, Article No. 82. [Google Scholar] [CrossRef] [PubMed]
|
|
[51]
|
Li, Y., Cong, Y., Jia, M., et al. (2021) Targeting IL-21 to Tu-mor-Reactive T Cells Enhances Memory T Cell Responses and Anti-PD-1 Antibody Therapy. Nature Communications, 12, 951. [Google Scholar] [CrossRef] [PubMed]
|
|
[52]
|
Chew, G.M., Fujita, T., Webb, G.M., et al. (2016) TIGIT Marks Exhausted T Cells, Correlates with Disease Progression, and Serves as a Target for Immune Restoration in HIV and SIV Infection. PLoS Pathogens, 12, e1005349.
|
|
[53]
|
Baruch, K., Deczkowska, A., Rosenzweig, N., et al. (2016) PD-1 Immune Checkpoint Blockade Reduces Pathology and Improves Memory in Mouse Models of Alzheimer’s Disease. Nature Medicine, 22, 135-137. [Google Scholar] [CrossRef] [PubMed]
|
|
[54]
|
Verma, V., Shrimali, R.K., Ahmad, S., et al. (2019) PD-1 Blockade in Sub-primed CD8 Cells Induces Dysfunctional PD-1+ CD38 HI Cells and Anti-PD-1 Resistance. Nature Immunology, 20, 1231-1243. [Google Scholar] [CrossRef] [PubMed]
|
|
[55]
|
Wang, X., Yang, X., Zhang, C., et al. (2020) Tumor Cell-Intrinsic PD-1 Receptor Is a Tumor Suppressor and Mediates Resistance to PD-1 Blockade Therapy. Proceedings of the National Academy of Sciences, 117, 6640-6650. [Google Scholar] [CrossRef] [PubMed]
|
|
[56]
|
Hayashi, H. and Nakagawa, K. (2020) Combination Therapy with PD-1 or PD-L1 Inhibitors for Cancer. International Journal of Clinical Oncology, 25, 818-830. [Google Scholar] [CrossRef] [PubMed]
|
|
[57]
|
Boutros, C., Tarhini, A., Routier, E., et al. (2016) Safety Pro-files of Anti-CTLA-4 and Anti-PD-1 Antibodies Alone and in Combination. Nature Reviews Clinical Oncology, 13, 473. [Google Scholar] [CrossRef] [PubMed]
|
|
[58]
|
Gainor, J.F., Shaw, A.T., Sequist, L.V., et al. (2016) EGFR Muta-tions and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis. Clinical Cancer Research, 22, 4585-4593. [Google Scholar] [CrossRef]
|
|
[59]
|
Oshima, Y., Tanimoto, T., Yuji, K., et al. (2018) EGFR-TKI-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients with Non-Small Cell Lung Cancer. JAMA Oncology, 4, 1112-1115. [Google Scholar] [CrossRef] [PubMed]
|
|
[60]
|
Perez-Ruiz, E., Minute, L., Otano, I., et al. (2019) Prophylactic TNF Blockade Uncouples Efficacy and Toxicity in Dual CTLA-4 and PD-1 Immunotherapy. Nature, 569, 428-432. [Google Scholar] [CrossRef] [PubMed]
|